9780521873796 Index.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Cambridge University Press 978-0-521-87379-6 - Infertility and Assisted Reproduction Edited by Botros R. M. B. Rizk, Juan A. Garcia-Velasco, Hassan N. Sallam and Antonis Makrigiannakis Index More information n index n abdominal pregnancy, 608, 620, 625 eggs/embryos, 587 contribution to circulating abortions. See also spontaneous good prognosis patients, 583–584 progesterone, 14 abortions number of treatments, 585–587 adrenal hyperplasia, 59, 205, 207, and hydrosalpinges, 79 poor prognosis patients, 582 286 role of trophoblastic oxidative stress, role of prolactin/cortisol, 587–590 advanced cardiac life support (ACLS), 637 research overview 77 sex-selective, 720 acupuncturist vs. needle inserters, Advanced Cell Technology company, therapeutic, 43 599 696 and unicornuate uterus, 329 biochemical studies, 580 Agarwal, S. K., 608 viewpoint of Vatican, 741–744 financial considerations, 601–602 age Academy of Andrology (Europe), 178 outcomes, 580 and ART acanthosis nigricans, 59–60, 286 patient identification, 578 patient selection/preparation, 349 acarbose, 291 good prognosis (GP), 580 success rates, 56 acquired thrombophilia inclusion criteria, 580 CC determination factors, 211 antiphospholipid antibody syndrome, poor prognosis (PPr), 580 influence on fertility rates 408 placebo effect vs. real phenomenon, fetal loss, Danish study, 57 mechanism of implantation 596–599 Hutterite data, 55–56 failure, 409 standard protocols vs. male factors, French study, 56 activins differentiation of syndromes, miscarriages, 56–57 and estrogen withdrawal, 221 578, 582, 596, 599 influence on reproductive influence on FSH, 10 utility of acupuncture consortium, efficiency, 55–57 inhibin/activin system, 12–13, 15 601 and IUI outcomes, 418 and steroidogenesis, 12 and stress hormones in IVF, and oocyte donation, 444–445 acupuncture. See also traditional 595–596 Aguilera, D. C., 568 Chinese medicine (TCM) studies/design, 580 Aitken, R. J., 170 basis for impact on fertility/IVF, 595 treatment protocols, 580 albumin modified Paulus protocol Addison disease, 339 albumin-containing medium, 182, post-embryo transfer, adhesion molecules 449 595 b-integrin, 42 and OHSS, 198, 249, 250–251 pre-embryo transfer, 595 prevention of embryo adhesion, 48 alcohol. See also fetal alcohol spectrum modified Stener-Victorin regulation of, 48 disorders (FASD) protocol, 595 role in folliculogenesis, 7–8 and caffeine consumption, 59, 351 electro-stimulation form, 576, 580 adhesions and dopamine agonist drugs, 278 IVF protocols, 581 cell-cell, 4 and fertility, 58–59, 371 procedure, pre-/post ET, 581 use of lasters and premature ejaculation, 188 statistical analysis, 581–582 intraperitoneal, 133–134 alfentanil, 77 evolution of use, with IVF, 592–595 intrauterine, 134 Almeida, O. D., 85 historical perspective, 577–578 adnexal masses, 60, 328, 622 Almodin, C. G., 711 ideal studies/RCTs, 599–600 in adolescent females, 87 Almog, B., 607 pulsatility index (PI) differential diagnosis, 89 Altered Nuclear Transfer (ANT) monitoring, 580–581 and ectopic pregnancy, 626 technique, for hESC RE&I initial reaction, 576 adolescent laparoscopy. See laparoscopy extraction, 697 research data/discussion pediatric/adolescent amenorrhea, 58, 276. See also premature all IVF patients, 584–585 adrenal glands ovarian failure (POF) demographics of impact, 590–592 adrenal hyperplasia vs. PCOS, 59 causes of, 62, 286 759 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-87379-6 - Infertility and Assisted Reproduction Edited by Botros R. M. B. Rizk, Juan A. Garcia-Velasco, Hassan N. Sallam and Antonis Makrigiannakis Index More information 760 n I NDEX n hypergonadotropic, evaluation, definition, 189 gestrinone, 310 343–344 incidence, 189 mifepristone, 311 and hyperprolactinemia, 276 anencephaly, 685 antipsychotic drugs, and hypothalamic amenorrhea, 62 anesthesia hyperprolactinemia, 275 and ovarian failure, 62 for fertiloscopy, 70 antithrombin deficiency, 407–408 secondary vs. primary, 339 for microlaparoscopy, 77–78 antral follicles. See also folliculogenesis; American College of Obstetrics and aneuploidy syndromes, 543. preantral follicles Gynecology, 423, 725 See also embryo acquisition of capillary networks, 3 American Fertility Society. See aneuploidy screening, PDG AMH influence on, 3 American Society for for, materials/methods characteristics, 3 Reproductive Medicine and blastomere asymmetry/ cyclic recruitment, 10 (ASRM) multinucleation, 523 development of, 3 American Society for Reproductive chromosomal, detection of, 162–163 expression of N-cadherin Medicine (ASRM), 116, 294, from cryopreservation, 458, 460 molecules, 7–8 335, 423 and male infertility, 182 growth of endometriosis categorization in older women, 56 androgens, 14 scheme, 320 and ovarian stimulation, 235 estrogens, 14 ethical nursing guidelines, 568 post-zygote aneuploidies, 650 follicle rescue/atresia, 13–14 ethics committee screening for, 522, 524 FSH intercycle rise, 11–12 gender selection issue, 720 of sperm, and DNA IGFs/IGFBPs, 13 perimenopausal fertility treatment, fragmentation, 633 inhibin/activin system, 12–13 725, 726 Angelman syndrome (AS), 679, 680, 687 steroids production, 12 recommendations/stance on anovulation ultrasound evaluation, 206 cryopreservation, 466, classifications of, 193 and VEGF, 3–4 474–475 and hyperandrogenism, 7 apoptosis (programmed cell death) and single embryo transfer, 519 hypogonadotropic anovulation, 194 assessment, in ejaculated sperm, stance on sperm and laparoscopic ovarian 169 cryopreservation, 466, 706 electrocautery, 297 and atresia, 14 American Urological Association, 188 and luteinized unruptured follicle apoptic factors, 14 Amin, K., 124 syndrome, 61 features/mechanisms of, 168–169 anastrozole, 126, 225, 313. See also medication FSH and, 10 letrozole clomiphene citrate, 195, 202, 210 of GCs/luteal cells, progesterone half-life, 289 DHEAS, 207 inhibition of, 7 side effects, 313 metformin, 195, 354 and male fertility, 169 anatomy mifepristone, 311 and male infertility, 169 fallopian tubes, 99–100 opioid receptor antagonists, 197 and Mu¨llerian tube regression, 115 androgens, 14 tamoxiphene, 195 presence in early CL, 5 as atretogenic factor, 14 normogonadotropic related genes, 5–7 increase of DNA fragmentation, 14 anovulation, 194, 195 p53 tumor suppressor, 5–7 presence in GCs of early antral and PCOS, 286, 294 Wilm’s tumor suppressor gene, 5 follicles, 14 and unexplained infertility, 333 appendectomy, incidental, 85–86 production/actions, 7 anti-angiogenesis therapy, for Appleton, Tim, 565 progesterone conversion to, by endometriosis, 314 Arbab, F., 608 P450c17 enzyme, 7 anticardiolipin (ACL), 412 arcuate uterus, 115, 122, 123, 330 transfer to granulosa cells, 12 anti-estrogen intervention, for argon lasers, 134, 294, 319 androstenedione, 3, 12, 32 ovulation induction. aromatase deficiency syndrome, 14 and aromatase enzyme, 220, 352 See also clomiphene aromatase inhibitors. See also cholesterol conversion to, 194 citrate (CC), for anastrozole; letrozole correlation with follicle diameter, 14 ovulation induction background information, 220 and endometriosis, 314 anti-Mullerian hormone (AMH) benefits to patient groups and HOXA-10 expression, 39 in cancer survivors, 708 endometriosis, 223 and PCOS, 286, 377 influence on FSH, 3, 10, 25–26 estrogen-dependant malignancy production during preovulatory inhibition of early development of survivors, 224 cycle, 3, 12 follicles in culture, 26–28 PCOS, 223–224 anejaculation, 182 as ovarian diagnostic marker, 62 poor responders, 223 causes/treatment antinuclear antigen (ANA), 412 for breast cancer, 220, 313 congenital, 189 antiphosphatidylserine (APS), 412 for endometriosis, 42, 313–314 idiopathic/psychogenic, 189 antiphospholipid antibody clinical basis for treatment with, infectious, 190 syndrome, 408 314 medications, 190 antiprogesterones, for endometriotic stromal cell neurological, 189–190 endometriosis, 310–311 expression, 313–314 surgical, 189 Cochrane database review of, 311 estradiol inactivation, 314 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-87379-6 - Infertility and Assisted Reproduction Edited by Botros R. M. B. Rizk, Juan A. Garcia-Velasco, Hassan N. Sallam and Antonis Makrigiannakis Index More information n I NDEX n 761 evidence for role in AR collection criteria/limitations, insulin-sensitizing drugs, 354 gonadotropin reduction in COH, 570–571 nitric oxide donors, 352 224 economic influences, 573 embryo transfer, 354–355 poor responder improved historical development, in U.S., 570 luteal phase management response, 224 Live Births per Embryo Transfer dose/timing of, 355–356 half-life, 225 (LB/ET) data, 571 methodology, 355 ovarian stimulation, mechanism for patient selection/management, need for, 355 central mechanisms, 221 572–573 ovarian stimulation protocol peripheral mechanisms, 221–222 report interpretation, 571–572 optimization, 351 in vitro maturation, 222 assisted reproductive technology patient selection/preparation ovarian stimulation safety concerns (ART), complications. age/duration of infertility, 349 low estrogen levels, 225 See also ectopic pregnancy; causes of infertility, 349–350 pregnancy outcomes, 225 miscarriages; multiple lifestyle factors/concurrent side effects of aromatase pregnancies; ovarian conditions, 349–351 inhibitors, 224–225 hyperstimulation assisted reproductive technology (ART), for ovulation induction, 196 syndrome (OHSS) religious perspective for PCOS treatment, 289 birth defects, 108 Coptic Church, 731 reduction of estrogen levels in clomiphene